Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Poland / NCT06662383
Active, not recruiting Phase 3

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

NCT06662383 · tracked via the Priya Life Science Poland tracker
Sponsor
Eli Lilly and Company
Phase
Phase 3
Started
2024-11-01
Last updated
2026-07-20

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

Retatrutide →Tirzepatide →

Retatrutide: Administered SC

Tirzepatide: Administered SC

Study summary

The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight. Exclusion Criteria: * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening. * Have a prior or planned surgical treatment for obesity. * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity. * Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening. * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2). * Have had within the past 90 days before screening: * acute myocardial infarction * cerebrovascular accident (stroke) * coronary revascularization * hospitalization for unstable angina, or * hospitalization due to congestive heart failure. * Have New York Heart Association Functional Classification Class IV congestive heart failure. * Have a history of chronic or acute pancreatitis.

Primary outcome measure(s)

  • Percent Change from Baseline in Body Weight — Baseline, Week 80

Trial sites (65)

FacilityCityRegionStatus
Medical Advancement Centers of Arizona Tempe Arizona
Mary & Dick Allen Diabetes Center Newport Beach California
Artemis Institute for Clinical Research San Diego California
Encompass Clinical Research Spring Valley California
Diablo Clinical Research, Inc. Walnut Creek California
Lynn Institute of Denver Aurora Colorado
Bridgeport Hospital Bridgeport Connecticut
Yale University School of Medicine New Haven Connecticut
Encore Medical Research Hollywood Florida
Suncoast Research Group Miami Florida
Onhealth Research Center Miami Florida
Precision Clinical Research Sunrise Florida
Einstein Clinical Research Vero Beach Florida
ClinCept Clinical Research - MH Columbus Georgia
Northeast Georgia Medical Center Gainesville Georgia
Pivotal Research Solutions Stonecrest Georgia
East-West Medical Research Institute Honolulu Hawaii
Northwestern University Chicago Illinois
Integrated Clinical Trial Services, Inc. West Des Moines Iowa
Pennington Biomedical Research Center Baton Rouge Louisiana
Great Lakes Research Group, Inc. Bay City Michigan
Great Lakes Research Institute Southfield Michigan
StudyMetrix Research City of Saint Peters Missouri
Las Vegas Endocrinology Henderson Nevada
Albany Medical College, Division of Community Endocrinology Albany New York
New York Gastroenterology Associates New York New York
Westchester Medical Center Valhalla New York
PharmQuest Life Sciences, LLC Greensboro North Carolina
Monroe Biomedical Research Monroe North Carolina
Accellacare - Wilmington Wilmington North Carolina
Lillestol Research Fargo North Dakota
PriMED Clinical Research Dayton Ohio
Tribe Clinical Research, LLC Greenville South Carolina
WR-Clinsearch, LLC Chattanooga Tennessee
Headlands Horizons LLC Brownsville Texas
Next Level Urgent Care Houston Texas
Houston Research Institute Houston Texas
Consano Clinical Research, LLC Shavano Park Texas
Chrysalis Clinical Research St. George Utah
Charlottesville Medical Research Charlottesville Virginia

+ 25 more sites — see the full list on the official registry below.

On this site

📄 Mounjaro (tirzepatide) drug profile →

More Eli Lilly and Company trials in Poland

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma Recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 Active, not recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) Recruiting

Other trials for the same condition

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes Active, not recruiting
Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis Recruiting
Białystok PLUS - Polish Longitudinal University Study Enrolling by invitation
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06662383 on ClinicalTrials.gov ↗ ← All trials in Poland